June 9th, 2025

评估转运体介导的 DDIs
For more expert insights on assessing transporter-mediated DDIs, read our white paper.

Vice President, Head of DMPK
Nathalie 为多家生物技术公司提供战略性 DMPK 和 ADME 发现服务、非临床 DMPK、临床药理学和监管科学服务。她还是药物相互作用科学卓越中心的核心团队成员。
Nathalie 在加拿大魁北克省拉瓦尔大学 Laval University 获得药学博士学位,研究肺癌化学预防,并完成了药物代谢方面的博士后研究。Nathalie 在制药行业拥有超过 20 年的生物技术、制药和 CRO 服务经验。在 Boehringher Ingelheim 公司担任多个抗病毒药物开发项目的 DMPK 实验室主任和项目负责人后,她转到 Epizyme 公司担任首席 DMPK 科学家。最近,她在 H3 Biomedicine 建立了 DMPK、生物分析和临床药理小组,负责整个发现和开发领域的战略和战术活动。

Sr. Director, Early Drug Development Services
In his current role with Certara, Dr. Heller provides consultancy services to pharmaceutical and biotech companies for non-clinical and clinical DMPK/ADME studies. This includes acting as project lead or strategic consultant to design and manage IND and NDA-enabling ADME programs for drug metabolism, PK, DDI, and radiolabel studies, project management, vendor management, report review and preparation, gap analysis, allometry, as well as conducting human radiolabel dosimetry estimations. In addition, Dr. Heller may serve as a virtual project team representative.
Dr. Heller has over 25 years’ experience providing scientific/technical leadership, consultancy, and operational CRO management to enable ADME and bioanalytical services, with depth in radiolabel studies from in vitro, non-clinical to clinical hAME studies and dosimetry.

Director, Early Drug Development Services, Certara Strategic Consulting
Federico provides strategic DMPK & ADME discovery services for several biotechnology companies. He is also an Associate Team Member in Innovation Engines in Drug Interaction Science.
Federico obtained his MsC in Physiology at Montreal University, Quebec, Canada. Federico has more than 20 years of experience in the pharmaceutical industry in biotech and pharma. After working for 15 years as a DMPK scientist at Boehringer Ingelheim Canada and USA, specializing in In vivo DMPK/In vitro ADME assays, he moved to Cambridge, MA and became a DMPK lead for H3 Biomedicine supporting multiple projects in oncology. Federico is now a DMPK consultant for Certara, helping his clients in early drug development up to clinical introduction.
联系我们